EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Preemptive Treatment of De Novo Donor Specific Anti-HLA Antibodies With IVIG Monotherapy after Lung Transplantation

Jennifer K McDermott, Skye J Castaneda, Sarah M Mietz, Cameron K Lawson, John A Gerlach, Ryan J Hadley, Gayathri Sathiyamoorthy, Sheila Krishnan, Edward T Murphy, Reda E Girgis

Transplant International · 2024

DOI: 10.3389/ti.2024.13431 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Transplant International, 2024. Verfasst von Jennifer K McDermott und 9 weiteren Autor:innen. Beteiligte Einrichtung: Richard DeVos Heart and Lung Transplant Program, Corewell Health and Michigan State University College of Human Medicine, Grand Rapids, MI, United St…. Hauptthemen laut MEDLINE: HLA Antigens, Immunoglobulins, Intravenous, Lung Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Development of de novo donor specific anti-HLA antibodies (dnDSA) following lung transplantation (LTX) is common and increases the risk for chronic lung allograft dysfunction (CLAD) and death. [1][2][3] Optimal management of asymptomatic dnDSA, in the absence of clinical antibody-mediated rejection or allograft dysfunction, is unclear. The approach varies among transplant centers. Some do not initiate specific therapy, while others pre-emptively treat with regimens that typically include high-dose intravenous immunoglobulin (IVIg). [4][5][6] A recent retrospective multi-center report found improved CLAD-free survival among 30 LTX recipients with asymptomatic dnDSA who received preemptive therapy compared with 115 controls who did not receive antibody-targeted therapy or were only treated once signs of AMR developed. Various antibody reduction strategies were employed, including intravenous immune globulin (IVIg) alone or in combination with rituximab, plasmapheresis, bortezomib, tocilizumab, and/or methylprednisolone. 6 IVIg has multiple immunomodulatory effects including neutralization of pathogenic IgG, inhibition of cytokine gene activation and activity, interaction with antigen-presenting cells to suppress T-cell activation, expansion of regulatory T-cells and inhibition of complement activity. 7,8 At our center, we routinely administer pre-emptive high dose IVIg monotherapy for asymptomatic dnDSA in an attempt to reduce the strength of the antibody and improve long-term outcomes. The aim of this study is to review our experience with this approach.This study was approved by our institutional review board. Data was collected from our prospective LTX registry. HLA antibody by Luminex single antigen bead assay was routinely obtained at post-op day 14, at 1-, 3-, 6-, 9-, 12-and 18-months post-transplant in conjunction with surveillance bronchoscopy with biopsy, yearly thereafter, and at any time for clinical indication. During the study period from 2/2013 and 3/2021, 230 lung transplants were performed. Sixty-three recipients (27%) developed dnDSA. Weexcluded 16 with a sum mean fluorescence intensity (MFI) < 3,000, 7 with clinical AMR at the time of first detection of dnDSA, 6 with non-HLA indication for IVIg and 2 re-transplants. The remaining 32 recipients with sum mean MFI ≥ 3,000 and no evidence of allograft dysfunction or AMR were treated with IVIg monotherapy at 2 gm/kg followed by 1 gm/kg monthly, for a minimum of 3 months or until clearance (sum MFI < 1,000) up to 6 months. The cohort was predominantly Caucasian (84%), bilateral LTX in 72%, 53% male with a median age of 62 (IQR:59, 67). During the observation period, CLAD had developed in 11 subjects and 10 died. CLAD-free survival at 2and 4-years post-transplant were 79% and 62%, respectively. In comparison, CLAD-free survival in a concurrent cohort of 128 recipients with no DSA was 92% and 77% at 2-and 4-years, respectively (P = 0.023 by log-rank comparison of Kaplan-Meir survival curves). We observed a trend towards a lower incidence of subsequent acute cellular rejection (61% vs. 93%; P = 0.05) and AMR (6% vs. 36%; P = 0.06) in those who cleared DSA compared with those with persistent DSA after IVIg.A large body of data has demonstrated a strong association between dnDSA, allograft rejection, and subsequent CLAD and mortality in lung transplant recipients. The association of stronger antibody (higher MFI) and complement fixing ability of dnDSA with worse outcomes and its detection prior to allograft I n r e v i e w dysfunction suggests that these antibodies may be involved in the pathogenesis of injury, rather than simply a marker of disease. 1,9 In this series of asymptomatic dnDSA lung transplant recipients, we observed significant reductions in dnDSA MFI following preemptive IVIg monotherapy with clearing in over half.In the absence of a control group, it is not possible to draw firm conclusions regarding the efficacy of this approach. Spontaneous clearing of dnDSA has been observed in up to one third of cases 1,10 and decreasing MFI in over half. 9 However, the definition of positive DSA in these reports was lower than our threshold MFI of 3000. Clinical outcome, in terms of CLAD-free survival, of this cohort was comparable to other studies where additional measures were employed, such as plasma exchange and B-cell depleting therapy. [4][5][6] While CLAD-free survival was lower than our concurrent DSA-negative group, it was similar to the DSA-negative cohort of Keller et al (2-yr CLAD-free survival of 70%) and markedly better than the no pre-emptive therapy DSA-positive group in that study (2-yr CLAD-free survival of 42%). 6 Taken together with the Keller study 6 , our findings suggest that preemptive therapy for asymptomatic dnDSA may improve long-term outcomes in this high-risk group. The use of IVIg monotherapy appears to yield similar results to those of combination strategies that are more cumbersome and associated with greater potential for complications. However, prospective, randomized controlled trials are required to definitively assess the efficacy of preemptive therapy and the optimal regimen. Analysis was performed with Wilcoxon rank sum test for paired samples.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HLA AntigensImmunoglobulins, IntravenousLung TransplantationAdultFemaleHumansMaleMiddle AgedGraft RejectionIsoantibodiesTissue Donors

Stichwörter der Autor:innen

CLAD-free survivalDSA de novoHLA antibodiesIVIGlung transplant

Substanzen

HLA AntigensImmunoglobulins, IntravenousIsoantibodies

Autor:innen und Institutionen

  • Richard DeVos Heart and Lung Transplant Program, Corewell Health and Michigan State University College of Human Medicine, Grand Rapids, MI, United States.
  • Biomedical Laboratory Diagnostics Program, Department of Medicine, Michigan State University College of Human Medicine, East Lansing, MI, United States.

Zitieren

APA

McDermott, J. K., Castaneda, S. J., Mietz, S. M., Lawson, C. K., Gerlach, J. A., Hadley, R. J., Sathiyamoorthy, G., Krishnan, S., Murphy, E. T., & Girgis, R. E. (2024). Preemptive Treatment of De Novo Donor Specific Anti-HLA Antibodies With IVIG Monotherapy after Lung Transplantation. Transplant International. https://doi.org/10.3389/ti.2024.13431

Vancouver

McDermott JK, Castaneda SJ, Mietz SM, Lawson CK, Gerlach JA, Hadley RJ, et al. Preemptive Treatment of De Novo Donor Specific Anti-HLA Antibodies With IVIG Monotherapy after Lung Transplantation. Transplant International. 2024. doi:10.3389/ti.2024.13431

BibTeX
@article{McDermott2024,
  author = {McDermott, Jennifer K and Castaneda, Skye J and Mietz, Sarah M and Lawson, Cameron K and Gerlach, John A and Hadley, Ryan J and Sathiyamoorthy, Gayathri and Krishnan, Sheila and Murphy, Edward T and Girgis, Reda E},
  title = {Preemptive Treatment of De Novo Donor Specific Anti-HLA Antibodies With IVIG Monotherapy after Lung Transplantation},
  journal = {Transplant International},
  year = {2024},
  doi = {10.3389/ti.2024.13431}
}
Kostenlos starten →